Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Cash from Operations: 2014-2025

Historic Cash from Operations for Viking Therapeutics (VKTX) over the last 12 years, with Sep 2025 value amounting to -$94.0 million.

  • Viking Therapeutics' Cash from Operations fell 328.03% to -$94.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$224.6 million, marking a year-over-year decrease of 202.46%. This contributed to the annual value of -$87.8 million for FY2024, which is 19.64% down from last year.
  • According to the latest figures from Q3 2025, Viking Therapeutics' Cash from Operations is -$94.0 million, which was down 99.75% from -$47.1 million recorded in Q2 2025.
  • Over the past 5 years, Viking Therapeutics' Cash from Operations peaked at -$6.1 million during Q1 2024, and registered a low of -$94.0 million during Q3 2025.
  • Its 3-year average for Cash from Operations is -$32.2 million, with a median of -$24.6 million in 2023.
  • Its Cash from Operations has fluctuated over the past 5 years, first soared by 75.11% in 2024, then tumbled by 753.13% in 2025.
  • Over the past 5 years, Viking Therapeutics' Cash from Operations (Quarterly) stood at -$12.3 million in 2021, then rose by 11.53% to -$10.9 million in 2022, then tumbled by 61.45% to -$17.6 million in 2023, then slumped by 76.76% to -$31.2 million in 2024, then plummeted by 328.03% to -$94.0 million in 2025.
  • Its Cash from Operations was -$94.0 million in Q3 2025, compared to -$47.1 million in Q2 2025 and -$52.3 million in Q1 2025.